Navigation Links
Myelodysplastic in Medical News

Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (deci...

A new agent for the treatment of patients with myelodysplastic syndrome; and more

A new agent for the treatment of patients with myelodysplastic syndrome In a paper published this week in PLoS Medicine, Azra Raza and colleagues (University of Massachusetts) use gene expression profiling to identify a molecular signature that predicts response to lenalidomide in patients wi...

Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting

* Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death Compared to Non-responders ATLANTA, Dec. 10 /PRNewswire-...

Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome

PALO ALTO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The d...

Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA

A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.// The exact cause of MDS is not known. However, increased i...

Drug increases hemoglobin in Myelodysplastic Syndrome

Patients with Bone marrow disorder Myelodysplastic Syndrome (MDS), treated with 500 mcg of Aranesp (Darbepoetin alfa) for every three weeks found to improve the hemoglobin content in 70% of patients. //The new drug Aranesp is manufactured by Amgen Biotech, which conducted a Phase II trial with 200 ...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...te Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia), and myelodysplastic Syndromes (MDS) (includes corresponding Graph/Chart) II-3 Table 2:...oma II-31 Non-Hodgkin's Lymphoma II-32 Hodgkin's Lymphoma II-32 myelodysplastic Syndromes II-32 Hematological Cancer Therapies II-33 Chemotherapy I...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's...

Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa

... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...

Telik Announces Preclinical Presentations at AACR Annual Meeting

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...
Myelodysplastic in Medical Technology

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been p...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for ...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) ...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

Reiterates 2008 Annual Financial Guidance DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, tod...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from a previously conducted Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous leukemia (AML) and high-risk m...

Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

- MAA submission based on data from largest Phase 3 study conducted in MDS - Vidaza therapy confers highly significant 9.4 month median overall survival advantage compared to conventional care regimens - Two year overall survival rate of 50.8% for Vidaza compared to 26.2% for ...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to conventional care regimens Only agent to demonstrate survival benefit in MDS compa...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium on Myelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented ...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigators reported today that Soliris(TM) (eculizumab), a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) developed by Alexion Pharmaceuticals, Inc. , is effective in patients diagnose...

Telik Announces Presentation at ASCO Annual Meeting

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's...
Myelodysplastic in Medical Definition

Hematopathology

...of Hematopoietic Cells The major disease of hematopoietic cells fall into several categories, which include chronic myeloproliferative disease , myelodysplastic syndromes , leukemias , lymphomas , plasma cell neoplasms , and histiocytic and mast cell neoplasms. Hematopathologists from all over the world h...
Myelodysplastic in Medical Dictionary

Myeloproliferative Disorders

...diseases ("MPD"s) are a group of diseases of the bone marrow in which excess cells are produced. They are related to, and may evolve into, myelodysplastic syndrome and acute myeloid leukemia, although the myeloproliferative diseases on the whole... Myeloproliferative disorders , Myeloprolif...

Epidemiology

...dents, and to provide graduate students in epidemiology with training that will allow them ... Descriptive Epidemiology and Clinical Course of myelodysplastic Syndromes within ... Genetic Epidemiology of Prostate Cancer (PROGRESS) (Stanford) ... Introduces the basic principles and methods of epidemiol...

Aplastic anemia

...ome cases of aplastic anemia are linked to benzene exposure, see our At ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. More about Aplastic Anemia : Causes and symptoms Diagnosis Treatment Prognosis Resources Aplastic Anemia Definition Aplastic ...

Aplastic

...gation Page. New ... In acquired aplastic anemia, clinical and laboratory ... Assists patients and families dealing with aplastic anemia and myelodysplastic syndromes. Aplastic anemia — Comprehensive overview covers symptoms, causes, treatment of this rare blood disorder. ... and serious condit...
Myelodysplastic in Biological News

The MDS foundation supports vidaza's recommendation for European approval

... The myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European ...ing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that ...

Vidaza receives positve opinion from European CHMP

...P) has awarded Vidaza (azacitidine) a positive opinion for the treatment of myelodysplastic syndromes (MDS) patients who are not eligible for stem cell transplants. ... approval shortly and quickly be available for patients across Europe." myelodysplastic syndromes (MDS) occur when the bone marrow stem cells malfunction. This re...

The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data

... Crosswicks, NJ (August 22, 2008) The myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Ad...ts with higher-risk MDS," said Kathy Heptinstall, Operating Director of the myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS wi...

Weill Cornell science briefs June/July 2008

... shrunk to normal sizes, and they began to produce normal red blood cells. The chemical (a similar compound is already in a Phase I clinical trial for myelodysplastic syndromes -- another blood disorder) blocks the activity of the JAK2 gene that is highly expressed in Cooley's anemia, and is believed to play a cruci...

Avoiding Spleen Removal for Cooley's Anemia SufferersAvoiding spleen removal for Cooley's anemia suf

... shrunk to normal sizes, and they began to produce normal red blood cells. The chemical (a similar compound is already in a Phase I clinical trial for myelodysplastic syndromes -- another blood disorder) blocks the activity of the JAK2 gene that is highly expressed in Cooley's anemia, and is believed to play a cruci...

Ireland Cancer Center researchers advance stem cell gene therapy

...to show evidence that genetic mutations are accumulating in marrow stem cells. This finding might be the key underlying the increased risk of anemias, myelodysplastic syndrome and acute leukemia in older individuals. Dr. Kevin Buntings laboratory gave two important presentations on how intracellular STAT5 (a...

NCI renewal grant to develop new cancer therapies

...f vorinostat, a histone deacetylase inhibitor, in combination with flavopiridol, a cell cycle inhibitor, in patients with refractory acute leukemia or myelodysplastic syndrome. Additionally, the team has recently received approval to lead a multi-institutional trial of vorinostat and bortezomib, a proteasome inh...

New molecules discovered that block cancer cells from modifying cell DNA

...ions that work to reverse the methylation process in cancer cells. They include azacitine (Vidaza) and decitabine (Dacogen), both for the treatment of myelodysplastic syndrome, diseases in which the production of blood cells by the bone marrow is disrupted. Vorinostat (Zolinza) also works to turn back on silenced ge...

New tool helps blood specialists improve patient care

...swering questions that determine compliance with pre-established performance measures developed by ASH that are important in the care of patients with myelodysplastic syndromes (MDS). "The hematologists who use these measures are not passive learners. They are not simply reading about how to improve patient care...

Long-term cancer risk follows stem cell transplant recipients

...ls from a female donor. Myeloablative, allogeneic HSCT is an effective standard therapy for specific life-threatening diseases, such as leukemia or myelodysplastic syndrome, for which blood cell lineages (which originate principally in the bone marrow and circulate in the blood) are abnormal. Destroying the patie...
Myelodysplastic in Biological Technology

EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes

Application to be reviewed under European Accelerated Assessment Procedure BOULDER, Colo., Feb. 7 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today announced that the European Medicines Agency (EMEA) has accepted for review the Company's Marketing Authorization Application (...

Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes

BOULDER, Colo., Aug. 29 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oral Azacitidine in the treatment of Myelodysplastic Syndromes (MDS). Fast Track programs are designe...

Telik Announces Second Quarter 2009 Financial Results

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders). In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy...

Telik Reports Preclinical Results at AACR Annual Meeting

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...nderway: (i) the continuation of the pivotal Phase II trial; (ii) a Phase III trial with standard remission-induction therapy in patients with AML and myelodysplastic syndromes (MDS); (iii) a Phase I/II trial in combination with cytarabine in elderly patients with AML; and (iv) a Phase I/II trial in combination with...

Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline

...st advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Teli...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

...ients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndromes (MDS). (7, 8, 9). In patients with thrombosis of unknown origin,...mori T, et al. Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes. Br J Haematol. 1998;102 (2):465-474. (9) Maciejewski JP,...

Telik Announces New TRAP Drug Discovery Agreement

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik...

Telik Announces Financial Results for 2008 Third Quarter

...advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik...
Other Tags
(Date:7/29/2014)... Gout was one called “the disease of ... that last statement essentially moot since many people of today ... not have are the resources to deal with such a ... maintain treatment for it, but the effects of the disease ... grinding halt. , Alternative medicine specialist and author ...
(Date:7/29/2014)... Maui, HI (PRWEB) July 29, 2014 Couples ... Seasons Resort Maui at Wailea. This September through November, ... of them free-- tailored to couples of all ages and ... and guests can take advantage of the Resort's popular ... $1,000 while the "twice yearly sale" is in full swing ...
(Date:7/29/2014)... 2014 In his latest blog post at ... CEO Per Wickstrom has listed 6 ways to light the ... creativity and avoid complacency, but for some it’s a losing ... progressive and powerful ways to help employees get to the ... as a whole.” , According to Per Wickstrom, 6 ways ...
(Date:7/29/2014)... Nuanced Media, a leading digital marketing agency, ... Insurance Portability and Accountability Act) certified firm. HIPAA ... transfer of Personal Health Information (PHI). By obtaining ... can effectively serve their medical industry clients. , The ... medical industry specific products such as medical websites ...
(Date:7/28/2014)... 2014 Treat skin to a true cleansing ... , Today and tomorrow only (while supplies last), take 40% ... is ideal for two specific users: , 1) those with ... bacteria free, and , 2) aging skin to help reduce ... Heshelow, founder of Sublime Beauty®. , Those with oily skin ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 3Health News:Per Wickstrom’s Latest Blog Post Lists 6 Ways to Light the “Fire” in Employees 2Health News:Nuanced Media Web Design Agency Now Hipaa Certified 2Health News:Clear, Clean Skin With the New Salicylic Wash from Sublime Beauty®; Enlivens Skin, Unclogs Pores 2
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
Other Contents